Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20530074 | 0.91 | FOLH1 (0.55) | KMT2ATLR2FOLH1HDAC1HDAC2 | |
| SCHEMBL20450605 | 0.90 | KMT2A (0.57) | KMT2ATLR2TLR1FOLH1 | |
| SCHEMBL20450575 | 0.90 | KMT2A (0.57) | KMT2ATLR2TLR1FOLH1 | |
| SCHEMBL20450603 | 0.90 | KMT2A (0.57) | KMT2ATLR2TLR1FOLH1 | |
| SCHEMBL20450573 | 0.90 | KMT2A (0.57) | KMT2ATLR2TLR1FOLH1 | |
| SCHEMBL30895551 | 0.89 | KMT2A (0.51) | KLK7KLK5KMT2ATLR2TLR1 | |
| SCHEMBL30895554 | 0.89 | KMT2A (0.51) | KLK7KLK5KMT2ATLR2TLR1 | |
| SCHEMBL17946769 | 0.89 | KLK7 (0.56) | KLK7KLK5KMT2AABCB1TLR2 | |
| SCHEMBL31298691 | 0.89 | KLK7 (0.56) | KLK7KLK5KMT2AABCB1MAPT | |
| SCHEMBL29370367 | 0.89 | KLK7 (0.56) | KLK7KLK5KMT2AABCB1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377175-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | CORNELL UNIVERSITY (US) | 2025-08-05 | — | — | US | disclosed |
| US-12268759-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | CORNELL UNIVERSITY (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240050599-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2024-02-15 | — | — | US | disclosed |
| US-20230285603-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230114130-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | COMELL UNIVERSITY (US) | 2023-04-13 | — | — | US | disclosed |
| US-11285227-B2 | Trifunctional constructs with tunablepharmacokinetics useful in imaging and anti-tumor therapies | CORNELL UNIVERSITY (US) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11285227-B2 | Trifunctional constructs with tunablepharmacokinetics useful in imaging and anti-tumor therapies | MC2R, OGFR, GLS | KLK7 855/4885KLK5 551/4885KMT2A 4100/4885 |
| US-20230114130-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, KRAS | KLK7 761/4885KLK5 545/4885KMT2A 3901/4885 |
| US-20230285603-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | KLK7 703/4885KLK5 538/4885KMT2A 3904/4885 |
| US-20240050599-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | KLK7 703/4885KLK5 538/4885KMT2A 3904/4885 |
| US-12377175-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | VHL, GLS, GPER1 | KLK7 703/4885KLK5 538/4885KMT2A 3904/4885 |
| US-12268759-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | VHL, GLS, GPER1 | KLK7 703/4885KLK5 538/4885KMT2A 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.